as 08-01-2025 4:00pm EST
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Upcoming Earnings Alert:
Get ready for potential market movements as Scholar Rock Holding Corporation SRRK prepares to release earnings report on 06 Aug 2025.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 3.2B | IPO Year: | 2018 |
Target Price: | $42.17 | AVG Volume (30 days): | 1.2M |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.78 | EPS Growth: | N/A |
52 Week Low/High: | $6.76 - $46.98 | Next Earning Date: | 08-06-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1960.31% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
FLIER JEFFREY S. | SRRK | Director | Jun 23 '25 | Sell | $32.70 | 31,452 | $1,024,721.98 | 26,836 | |
Parlavecchio Caryn | SRRK | CHRO | Jun 16 '25 | Sell | $32.00 | 6,186 | $197,960.66 | 157,642 | |
Ho Junlin | SRRK | GENERAL COUNSEL | Jun 16 '25 | Sell | $32.00 | 7,442 | $238,154.42 | 222,569 | |
Peng Katie | SRRK | Director | Jun 16 '25 | Sell | $32.24 | 3,031 | $96,888.38 | 34,920 | |
Burow Kristina | SRRK | Director | May 29 '25 | Sell | $29.54 | 5,400 | $160,510.62 | 25,471 | |
Reed Joshua | SRRK | Director | May 29 '25 | Sell | $29.86 | 5,400 | $160,462.57 | 16,232 | |
Brudnick Richard | SRRK | Director | May 29 '25 | Sell | $29.82 | 6,075 | $180,530.67 | 16,457 | |
Vaishnaw Akshay | SRRK | President of R&D | May 29 '25 | Sell | $29.82 | 6,750 | $200,612.03 | 617,825 | |
Gilman Michael | SRRK | Director | May 29 '25 | Sell | $29.53 | 3,375 | $100,304.05 | 57,961 |
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
Reuters
a month ago
Insider Monkey
a month ago
Motley Fool
a month ago
Investopedia
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
MT Newswires
a month ago
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.